Supplies overhaul the Municipal Commission for Discipline Inspection supervision assigned to 12 groups of full-process supervision

Pharmaceutical Network February 8th, closely follow the supplies tender, procurement February 7th, according to the Shenzhen Municipal Commission for Discipline Inspection official micro "clean Shenzhen" news, the Municipal Commission for Discipline Inspection posted 12 groups, closely follow the "four key", regulate the procurement of medical supplies, the group will conduct in-depth research on the situation of medical supplies, the municipal medical insurance bureau to carry out special supervision, closely follow the selection of key posts cadres, appointment, solid development Integrity audit, pre-service talks and daily supervision, will promote the introduction of "Shenzhen city governance of high-value medical supplies reform implementation plan and related policy provisions", co-ordinate the bidding and procurement of medical supplies and other matters, strengthen supervision of key links;
notice states that the more regulated the purchase of consumables, the less room there is for rent-seeking.
The 12th Discipline Inspection and Supervision Group (hereinafter referred to as the "Twelve Groups") of the Municipal Commission for Discipline Inspection and Supervision has closely followed key posts, key links, key processes and key nodes, and, on the basis of promoting the group procurement of pharmaceuticals, urged the Municipal Health Insurance Bureau to standardize the procurement of medical supplies and to be optimistic about the "money bag" of the medical insurance fund.
The person in charge of the 12 groups stationed in the
said: "To the crown stent, for example, from January 2021, the city has such surgery qualifications and can participate in the national centralized procurement of 16 medical institutions, has all started to purchase high-quality and low-cost crown stent, this one alone will save the public 130 million yuan."
" next step, the group will further strengthen the supervision of key areas and key links, and promote the health care industry to clean up.
companies also check the dealer process of supervision including products, but also involved in product sales and transportation of people.
February 7, the Guangdong Pharmaceutical Trading Center issued a Notice on the Reporting of Information on The Misconduct of Pharmaceutical Enterprises, which stated that pharmaceutical enterprises will carry out information reporting on the misconduct of pharmaceutical enterprises in Guangdong Province.
the main body of the report includes: participating in or entrusting to participate in the centralized procurement of pharmaceutical and medical supplies in Guangdong Province, the platform network, as well as public medical institutions and non-public medical institutions designated for medical insurance to carry out independent procurement of pharmaceutical enterprises (including drug production license holders, pharmaceutical and medical supplies production enterprises, distribution enterprises with the production enterprises have a proxy relationship, and distribution enterprises).
, the drug listing license holder includes the domestic agent designated by the overseas drug listing license holder.
in the contents of the report, the notice states that since August 28, 2020, pharmaceutical enterprises and their employees, entrusted agent enterprises in our province, "pharmaceutical prices and recruitment matters list (2020 edition)" list of acts of disrelieving, according to law If the person who is liable or causes the object of bribery is held accountable according to law (including the circumstances in which the fact of the violation of the law is found but the decision is not to prosecute or punish), the pharmaceutical enterprise shall, as required, submit a written report to the provincial platform on the 30th (natural day) from the date of the effective date of the court's judgment or the administrative penalty decision of the department.
pharmaceutical enterprises shall report information in a timely, comprehensive, complete and standardized manner, and shall not be concealed, underreported or unreported.
For pharmaceutical enterprises that have not taken the initiative to report information about their misre facts to the provincial platform, if they are verified or verified by the report, the provincial platform will record and process the enterprises according to the pharmaceutical price and credit evaluation.
pharmaceutical enterprises to appeal judgments, administrative penalty decisions or administrative review, administrative proceedings, does not affect the requirements of the provincial platform to report the information of the misconduct.
Major violations will be cancelled the list includes 7 items: 1. Pharmaceutical purchase and sale, to all levels of medical institutions, centralized procurement agencies and their staff rebates or other improper benefits; 2. obtain false VAT invoices (except for false VAT invoices in good faith); 3. Because of their own or related enterprises to implement monopoly agreements, abuse of market dominance, etc., not actively correct the unfair high prices of the products involved; To promote excessive price increases and other violations of the Price Law; 5. Pharmaceutical enterprises, because of improper price behavior, are consulted, investigated, interviewed, cautioned, inspected by the competent pharmaceutical price authorities, push, refuse, fail to fully explain the reasons or make false commitments; 6. Bid at below-cost quotations, bid for fraud, bid rigging, abuse of market dominance, etc., to disrupt the centralized procurement order; 7. Refuse to fulfill the commitments or refuse to perform the contract without justification.
the above evaluation system is applicable to centralized procurement of pharmaceutical and medical supplies, platform networking, as well as public medical institutions and non-public medical institutions targeted for medical insurance for the record procurement.
pharmaceutical enterprises and pharmaceutical products operating only outside the centralized procurement market are not included in the scope of evaluation.
The Code of Practice shows that the arms enterprises will also be graded for the responsibility of failure of trust, the registration of a total of "general," "medium," "serious", "particularly serious."
Among them, pharmaceutical enterprises rated as "serious" for loss of trust, in addition to warning, warning risks, should limit or suspend the enterprise involved in drugs or medical supplies hanging network, bidding or distribution qualifications, limit or suspend the period according to the pharmaceutical enterprise credit repair behavior and results of timely adjustment.
For pharmaceutical enterprises rated as "particularly serious", in addition to warning and warning of risks, the enterprise shall be restricted or suspended all drugs and medical supplies hanging network, bidding or distribution qualifications, restrictions or suspension period according to the pharmaceutical enterprise credit repair behavior and results of timely adjustment.